| DB ID | MyCo_2493 |
| Title | IL-17 in plasma and bronchoalveolar lavage fluid in non-neutropenic patients with invasive pulmonary aspergillosis |
| Year | 2024 |
| PMID | 39176263 |
| Fungal Diseases involved | Invasive pulmonary aspergillosis |
| Associated Medical Condition | None |
| Genus | Aspergillus |
| Species | spp. |
| Organism | Aspergillus spp. |
| Ethical Statement | The study was approved by the Institutional Review Board of Changzhou first people’s Hospital. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. |
| Site of Infection | None |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Bronchoalveolar lavage fluid (BALF) |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | GM |
| Biomarker Full Name | Galactomannan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | China |
| Cohort | A total of 281 patients were enrolled in this study, of which 62 had proven or probable IPA and the remaining 219 patients were controls. |
| Cohort No. | 62 Patients 219 control |
| Age Group | 53-71 |
| P Value | None |
| Sensitivity | 0.687 |
| Specificity | 0.919 |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Invasive pulmonary aspergillosis (IPA) is a life-threatening fungal infection predominantly affecting neutropenic patients. These patients generally have severe immune suppression, such as malignant hematological diseases, solid organ or hematopoietic stem cell transplantation, etc. In non-neutropenic patients, IPA is relatively uncommon but can occur in individuals with other underlying risk factors, such as chronic obstructive pulmonary disease (COPD) or bronchiectasis. The diagnosis of IPA in non-neutropenic patients is challenging due to the lack of specific clinical and radiological manifestations. Traditional diagnostic methods, such as culture and histopathology, have limited sensitivity and specificity, leading to delayed diagnosis and treatment. |
| Technique | ELISA |
| Analysis Method | ELISA Based |
| ELISA kits | ELISA Kit- Platelia Aspergillus (Platelia Aspergillus Kit, Bio-Rad Laboratories, CA, USA), IL-17 ELISA Kit (Human IL-17 ELISA Kit, Abcam) |
| Assay Data | None |
| Validation Techniques used | FDA Approved -Platelia Aspergillus ELISA |
| Up Regulation Down Regulation | Increase |
| Sequence Data | None |
| External Link | None |
